Paracetamol

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
星期二, 四月 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
星期五, 四月 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

Aleve® Speaks The Painful Truth, Encouraging Consumers to Explore Their Pain Management Options

Retrieved on: 
星期一, 三月 25, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Aromatherapy, National Consumers League, Hydrocodone, MAPDA, NCL, Partnership, Mother, Education, Patient, Yoga, Paracetamol, Opioid use disorder, Naproxen, Trial of the century, Bayer, Meditation, OTC, CDC, Love, Pain, Multimedia, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240325938118/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325938118/en/
    Aleve launches "The Painful Truth" campaign with Mothers Against Prescription Drug Abuse (MAPDA) and National Consumers League (NCL).
  • (Photo: Business Wire)
    While opioid dispensing rates in the U.S. are slowly ticking down, they remain elevated compared with rates in other countries.
  • “The Painful Truth” campaign launches with a three-minute film featuring real pain sufferers who are at crossroads in their pain relief journeys and seeking guidance.
  • At this critical juncture in their care, the patients are encouraged to consider different pain relief options.

Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™ Diaper Rash Crème Spray

Retrieved on: 
星期四, 三月 28, 2024
Convenience, Zinc oxide, Chamomile, Dermatitis, Amazon, Paraben, Paracetamol, TLC, OTC, Skin, Fever, Safety, Pain, Parent

HAWTHORNE, N.Y., March 28, 2024 /PRNewswire/ -- While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which is formulated with 10% zinc oxide, organic chamomile and calendula, effortlessly covers the affected area, creating a protective barrier that helps soothe baby's diaper rash while allowing skin to breath and heal. It's gentle enough to use at each diaper change to help prevent future irritation.

Key Points: 
  • Made with TLC – Thin Layer Care™ Technology, New bébé Bottoms™ Diaper Rash Crème Spray Combines Zinc Oxide (10%) with Soothing Chamomile and Calendula in a Convenient, No-Touch Spray Application
    HAWTHORNE, N.Y., March 28, 2024 /PRNewswire/ -- While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed.
  • It's gentle enough to use at each diaper change to help prevent future irritation.
  • Though gentle, new bébé Bottoms is made with 10% zinc oxide, which is dermatologically tested in its efficacy for both preventing and treating diaper rash.
  • New bébé Bottoms Diaper Rash Crème Spray is available to purchase on Amazon and will expand to other major retailers in the coming months.

CPSC Warns that Narcotics and Water Beads Are Growing Risks Facing Young Children

Retrieved on: 
星期二, 三月 19, 2024
Narcotic, Toxicity, National Poison Prevention Week, Poisoning, Environment, CPSC, Caregiver, Risk, Child, Acrylamide, Paracetamol, Death, Heart, Water, Safety, Injury, Ibuprofen

WASHINGTON, March 19, 2024 /PRNewswire/ -- During National Poison Prevention Week, the U.S. Consumer Product Safety Commission (CPSC) is highlighting serious, growing hazards facing young children, including a surge in unintentional poisoning from narcotics, and additional hazards identified with water bead products. 

Key Points: 
  • WASHINGTON, March 19, 2024 /PRNewswire/ -- During National Poison Prevention Week, the U.S. Consumer Product Safety Commission (CPSC) is highlighting serious, growing hazards facing young children, including a surge in unintentional poisoning from narcotics, and additional hazards identified with water bead products.
  • The large water beads in CPSC's warnings contain levels of acrylamide in violation of the Federal Hazardous Substances Act.
  • CPSC Recommendation: Remove water beads from any environment where young children may be present.
  • Store water beads in a secure container and location where young children cannot easily access them.

New Practice Guideline Co-Led by Penn Dental Medicine Details Dental Pain Management Strategies

Retrieved on: 
星期三, 三月 13, 2024
Dental care, JADA, Dentistry, Associate, Patient, Naproxen, Nonsteroidal anti-inflammatory drug, University, Paracetamol, American Dental Association, Wilfrid Sellars, Prescription, Risk, Toothache, Analgesic, Pain, Ibuprofen, Guideline

PHILADELPHIA, March 13, 2024 /PRNewswire/ -- A new clinical practice guideline for managing acute dental pain in adolescents and adults has been released, recommending nonsteroidal anti-inflammatory drugs (NSAIDs) taken alone or with acetaminophen as first-line treatments for managing short-term dental pain.

Key Points: 
  • PHILADELPHIA, March 13, 2024 /PRNewswire/ -- A new clinical practice guideline for managing acute dental pain in adolescents and adults has been released, recommending nonsteroidal anti-inflammatory drugs (NSAIDs) taken alone or with acetaminophen as first-line treatments for managing short-term dental pain.
  • The guideline was developed by Penn Dental Medicine's Center for Integrative Global Oral Health (CIGOH) , the American Dental Association (ADA), and the University of Pittsburgh School of Dental Medicine.
  • Dr. Alonso Carrasco-Labra, Associate Professor and Director of the Cochrane Oral Health Collaborating Center at Penn Dental Medicine, and Olivia Urquhart, an epidemiologist and instructor within CIGOH, co-led its development.
  • This is the second of two guidelines on acute dental pain management from this research team.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
星期二, 二月 27, 2024
Fever, Ibuprofen, Clarithromycin, PIN, Lactulose, Multimedia, FDA, Acetylcysteine, Pain, Omeprazole, Granisetron, Amoxicillin, Idiopathic pulmonary fibrosis, Skin, Nausea, Vomiting, Constipation, Duchenne muscular dystrophy, Cardiomyopathy, Fungal infection, Hyponatremia, Paracetamol, Health, Patient, Helicobacter pylori, Infection, Gastroenterology

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

InventHelp Inventors Develop New Fever Pops for Children (AJD-203)

Retrieved on: 
星期三, 二月 14, 2024
Fever, Hospital, Ibuprofen, Multimedia, Suite, Pain, Sale, Parent, FEVER, Invention, Paracetamol, Patient, Child

Our flavorful design would help reduce fever and pain while also providing added hydration."

Key Points: 
  • Our flavorful design would help reduce fever and pain while also providing added hydration."
  • The patent-pending invention provides a new way to administer ibuprofen or acetaminophen to children.
  • The invention features a unique design that is easy to consume so it is ideal for parents with young children, hospitals, etc.
  • 22-AJD-203, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Shriners Children's Doctor Alerts Parents of Overlooked Dangers of Microwave Soups and Noodles During National Burn Awareness Week

Retrieved on: 
星期一, 二月 5, 2024
Smoke, Parent, American College, Cheese, Clothing, PubMed, Burn, Child, Patient, Pain, Blister, Water, Paracetamol, Food, Occupational therapy, Skin, ABA, Eating, Senior counsel, American Burn Association, Ibuprofen, ACS, Butter, Bullying

Dr. David Greenhalgh, Chief of Burns at Shriners Children's Northern California, has spent more than 35 years working with pediatric burn patients.

Key Points: 
  • Dr. David Greenhalgh, Chief of Burns at Shriners Children's Northern California, has spent more than 35 years working with pediatric burn patients.
  • Now, the primary culprit is scalding injuries from simple items people forget are dangerous, such as hot liquids and microwave foods.
  • He says while convincing companies to change their packaging for products is a difficult and lengthy process, parents need to be aware of the dangers.
  • All three Shriners Children's burn care locations across the country are accredited by the American Burn Association (ABA) and the American College of Surgeons (ACS) as verified pediatric burn centers.

Hikma announces US launch of COMBOGESIC® IV

Retrieved on: 
星期一, 二月 5, 2024
AFT, NSAID, Patient, Pain, Paracetamol, Pain management, Hikma Pharmaceuticals, Ibuprofen, Health, Hospital, Pharmaceutical industry

LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.

Key Points: 
  • LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.
  • COMBOGESIC® IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID).
  • In 2021, Hikma signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialization of COMBOGESIC® IV in the US.
  • Under the trade name of MAXIGESIC® IV outside of the United States, COMBOGESIC® IV is licensed in over 100 countries and marketed in over 20 countries.